Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients

Bristol Myers Squibb Co BMY announced the first disclosure of results from the primary analysis of the pivotal TRANSCEND CLL 004 Phase 1/2 study of Breyanzi (lisocabtagene maraleucel, liso-cel) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
At a median follow-up of 21.1 months, results show that Breyanzi delivered statistically significant complete response (CR) rates, the study's primary endpoint, in 18.4% of patients in the primary efficacy analysis set.
Related: Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration.
Among patients who achieved a CR, no disease progression or deaths were observed, with the median duration of response not reached.
High rates of undetectable minimal residual disease (uMRD) were observed across patients treated with Breyanzi, with a uMRD rate of 63.3% in the blood and 59.2% in the bone marrow, associated with increased progression-free survival.
The overall response rate (ORR) was 42.9%, with a median duration of response of 35.3 months.
The company also announced the first results from the Phase 3 COMMANDS study of Reblozyl (luspatercept-aamt) versus epoetin alfa, an erythropoiesis-stimulating agent (ESA), for anemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes.
Data showed that 58.5% of the patients treated with Reblozyl achieved transfusion independence with concurrent hemoglobin increase vs. epoetin alfa (31.2%).
Reblozyl demonstrated a durable response, with nearly 2.5 years median transfusion independence, one year longer than epoetin alfa.
Transfusion independence of at least 24 weeks was achieved by 47.6% of Reblozyl patients vs. 29.2% of epoetin alfa patients.
Price Action: BMY shares are up 0.22% at $64.70 premarket on the last check Friday.

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments